“…Continuation of medical treatment for UC during pregnancy is recommended due to the increased risk of active disease and poor pregnancy outcomes associated with interruption of treatment. 4 In the interventional studies of tofacitinib in UC, there were 11 cases of maternal exposure, all patients were exposed during the first trimester, specific gestational age at the time of exposure could not be determined, and all patients except one were on 10 mg twice a day dose. Four healthy newborns 36.4%, two spontaneous abortions 18.2%, and two medication terminations 18.2% were reported, and three were pending or lost to follow-up 27.2%.…”